Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class (Ascending) Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00006-0461-02 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-06 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 April 30, 2020 In Use
00006-0461-12 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 In Use
00006-0461-30 00006-0461 Aprepitant Emend 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral March 26, 2003 July 14, 2010 In Use
00006-3884-01 00006-3884 Fosaprepitant Dimeglumine Emend Ancillary Therapy Antiemetic Substance P/Neurokinin 1 July 8, 2010 July 31, 2012 No Longer Used
00006-3884-32 00006-3884 Fosaprepitant Dimeglumine Emend Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Jan. 25, 2008 July 31, 2012 No Longer Used
68071-2763-03 68071-2763 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 15, 2022 In Use
76045-0216-20 76045-0216 ONDANSETRON HYDROCHLORIDE ONDANSETRON 4.0 mg/2mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous May 31, 2022 In Use
70518-2650-00 70518-2650 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous March 25, 2020 In Use
51662-1288-01 51662-1288 METOCLOPRAMIDE METOCLOPRAMIDE 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sept. 22, 2018 In Use
51662-1288-03 51662-1288 METOCLOPRAMIDE METOCLOPRAMIDE 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Oct. 1, 2022 In Use
55700-0952-65 55700-0952 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 11, 2022 In Use
57237-0075-30 57237-0075 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
57237-0075-50 57237-0075 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 4, 2022 In Use
57237-0076-30 57237-0076 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
57237-0076-50 57237-0076 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 4, 2022 In Use
60760-0567-10 60760-0567 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 25, 2022 In Use
63629-9166-01 63629-9166 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral Feb. 21, 2022 In Use
67457-0769-02 67457-0769 ONDANSETRON HYDROCHLORIDE ONDANSETRON HYDROCHLORIDE 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 31, 2017 In Use
69339-0171-03 69339-0171 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0171-05 69339-0171 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0172-03 69339-0172 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
69339-0172-05 69339-0172 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 24, 2022 In Use
70860-0785-05 70860-0785 Palonosetron hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2022 In Use
16729-0240-03 16729-0240 FOSAPREPITANT Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Oct. 22, 2020 In Use

Found 10,000 results in 7 millisecondsExport these results